Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Spinal Modulation NV

Tech Transfer Roundup: MD Anderson Tackles Cancer In Alliances With UroGen, Xencor, Obsidian

In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.

Tech Transfer Round-Up Deals

St. Jude: Neuromodulators Could Be Key To Fighting Opioid Epidemic

As public-health officials continue to fight the opioid epidemic, a top executive at St. Jude Medical says neuromodulators can play a central role in providing better treatment options.

Medical Device Business Strategies

St. Jude's Newly Approved Axium Stimulator Could Be Market Game-Changer

St. Jude followed through on its 2015 acquisition of start-up Spinal Modulation with an FDA approval of the Axium neurostimulator for chronic intractable pain. It's the first such device to target the dorsal root ganglion and could expand the overall size of the spinal cord stimulation market.

Medical Device Clinical Trials

Neuro Medtech Investors Have Time (And Money) For The Pain

START-UP reviews five years of fundraising and exit activities for privately held medtech and diagnostics companies developing neurology treatments. Part 2 of our series on neuro-focused capital raising and bow-outs.

Medical Device
See All

Company Information